Partnership for Vivax Elimination (PAVE) Feasibility Studies and Operational Research
The Partnership for Vivax Elimination (PAVE) is led by Medicines for Malaria Venture (MMV) and PATH. A key objective of PAVE is to conduct feasibility studies and operational research supporting Ministries of Health in malaria endemic countries to look at the best way to use different P. vivax relapse treatments and diagnostics at different levels of the healthcare system in support of their elimination goals. Please see the links in the sidebar to learn more about the research planned or currently taking place under the PAVE initiative in Brazil, Ethiopia, India, Indonesia, Lao PDR, Papua New Guinea, Peru, Thailand and Vietnam.
PAVE combines investments from Unitaid, the Bill & Melinda Gates Foundation, the UK Foreign, Commonwealth and Development Office (FCDO) and MMV core funding, among others. The feasibility studies planned in Ethiopia, India, Indonesia, Peru and PNG are funded by Unitaid.